The number of so-called pay-to-delay deals declined in fiscal year 2015, the second consecutive year that a drop occurred since the U.S. Supreme Court ruled these controversial agreements can be subject to antitrust scrutiny, according to the latest tally by the Federal Trade Commission.

The FTC has kept a watchful eye on these deals, which involve settlements of patent litigation between brand-name and generic drug makers, over concerns that some violate antitrust laws. The agency, which has gone to court several times to argue this point, has in the past claimed these deals cost U.S. consumers an estimated $3.5 billion annually.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy